Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 temozolomide in MGMT-methylated advanced aerodigestive tract cancers
2006-003169-15Phase 2Terminated
- Sponsor
- Merck & Co.
- Start
- Nov 2006
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of temozolomide in colorectal cancer (CRC), non-small cell lung cancer (NSCLC), head and neck cancer (HNC) and 1 more, sponsored by Merck & Co. Primary endpoint: Response rate. Started Nov 2006; status: terminated.
02
Drugs
temozolomide
03
Conditions
colorectal cancer (CRC)non-small cell lung cancer (NSCLC)head and neck cancer (HNC)esophageal cancer
Beyond the preview
Go deeper on 2006-003169-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-003169-15.